nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—psoriasis	0.549	1	CbGaD
Gliclazide—ALB—Acitretin—psoriasis	0.066	0.277	CbGbCtD
Gliclazide—ALB—Mycophenolate mofetil—psoriasis	0.0309	0.13	CbGbCtD
Gliclazide—ALB—Prednisone—psoriasis	0.0247	0.104	CbGbCtD
Gliclazide—CYP2C19—Cholecalciferol—psoriasis	0.0231	0.0969	CbGbCtD
Gliclazide—CYP2C9—Cholecalciferol—psoriasis	0.0192	0.0806	CbGbCtD
Gliclazide—CYP2C19—Prednisone—psoriasis	0.016	0.0672	CbGbCtD
Gliclazide—CYP2C19—Cyclosporine—psoriasis	0.0152	0.0637	CbGbCtD
Gliclazide—CYP2C9—Cyclosporine—psoriasis	0.0126	0.0529	CbGbCtD
Gliclazide—ALB—Methotrexate—psoriasis	0.0124	0.052	CbGbCtD
Gliclazide—CYP2C19—Dexamethasone—psoriasis	0.01	0.0419	CbGbCtD
Gliclazide—CYP2C9—Dexamethasone—psoriasis	0.00831	0.0349	CbGbCtD
Gliclazide—VEGFA—Allograft Rejection—IL22—psoriasis	0.00195	0.0758	CbGpPWpGaD
Gliclazide—CYP2C19—CYP2E1 reactions—CYP2S1—psoriasis	0.00124	0.0483	CbGpPWpGaD
Gliclazide—CYP2C9—CYP2E1 reactions—CYP2S1—psoriasis	0.00113	0.044	CbGpPWpGaD
Gliclazide—Glipizide—PPARG—psoriasis	0.000926	1	CrCbGaD
Gliclazide—CYP2C19—Xenobiotics—CYP2S1—psoriasis	0.000768	0.0299	CbGpPWpGaD
Gliclazide—CYP2C9—Xenobiotics—CYP2S1—psoriasis	0.0007	0.0273	CbGpPWpGaD
Gliclazide—VEGFA—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKBIA—psoriasis	0.00063	0.0246	CbGpPWpGaD
Gliclazide—VEGFA—Endochondral Ossification—RUNX3—psoriasis	0.000549	0.0214	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—CP—psoriasis	0.000478	0.0186	CbGpPWpGaD
Gliclazide—VEGFA—Alpha9 beta1 integrin signaling events—NOS2—psoriasis	0.000441	0.0172	CbGpPWpGaD
Gliclazide—VEGFA—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—JUN—psoriasis	0.000418	0.0163	CbGpPWpGaD
Gliclazide—VEGFA—Hypertrophy Model—IFNG—psoriasis	0.000404	0.0158	CbGpPWpGaD
Gliclazide—VEGFA—Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis—NFKB1—psoriasis	0.000402	0.0157	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—HLA-C—psoriasis	0.000369	0.0144	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL13—psoriasis	0.000366	0.0143	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—ZMIZ1—psoriasis	0.000365	0.0142	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL17A—psoriasis	0.000337	0.0131	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—SERPINB8—psoriasis	0.000334	0.013	CbGpPWpGaD
Gliclazide—VEGFA—Dexamethasone—Clobetasol propionate—psoriasis	0.000332	0.0968	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Clobetasol propionate—psoriasis	0.000332	0.0968	CbGdCrCtD
Gliclazide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000319	0.0124	CbGpPWpGaD
Gliclazide—CYP2C19—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000315	0.0123	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL12B—psoriasis	0.000313	0.0122	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—HLA-E—psoriasis	0.000306	0.0119	CbGpPWpGaD
Gliclazide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP2S1—psoriasis	0.000291	0.0113	CbGpPWpGaD
Gliclazide—CYP2C9—Oxidation by Cytochrome P450—CYP2S1—psoriasis	0.000287	0.0112	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—TYK2—psoriasis	0.000283	0.011	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—RUNX3—psoriasis	0.000269	0.0105	CbGpPWpGaD
Gliclazide—VEGFA—Betamethasone—Beclomethasone—psoriasis	0.000266	0.0776	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Fluocinonide—psoriasis	0.000266	0.0776	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Beclomethasone—psoriasis	0.000266	0.0776	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Fluocinonide—psoriasis	0.000266	0.0776	CbGdCrCtD
Gliclazide—VEGFA—Bladder Cancer—CXCL8—psoriasis	0.000265	0.0103	CbGpPWpGaD
Gliclazide—CYP2C19—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000259	0.0101	CbGpPWpGaD
Gliclazide—VEGFA—Dexamethasone—Fluocinolone Acetonide—psoriasis	0.000258	0.0754	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Fluocinolone Acetonide—psoriasis	0.000258	0.0754	CbGdCrCtD
Gliclazide—KCNJ11—Type II diabetes mellitus—TNF—psoriasis	0.000257	0.01	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTTG1—psoriasis	0.000253	0.00986	CbGpPWpGaD
Gliclazide—ALB—HDL-mediated lipid transport—APOE—psoriasis	0.000251	0.00979	CbGpPWpGaD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—CYP2S1—psoriasis	0.000236	0.00918	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL10—psoriasis	0.000229	0.00893	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IL4—psoriasis	0.000223	0.00868	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—HLA-B—psoriasis	0.000218	0.00849	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—LEP—psoriasis	0.000218	0.00848	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL13—psoriasis	0.000213	0.00828	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—ITGAL—psoriasis	0.000212	0.00827	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—NFKBIA—psoriasis	0.000205	0.008	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—NOS2—psoriasis	0.000203	0.0079	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—HLA-A—psoriasis	0.000202	0.00787	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—HLA-DRB1—psoriasis	0.000185	0.00719	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—STAT3—psoriasis	0.000174	0.00677	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—NFKB1—psoriasis	0.000173	0.00673	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IFNG—psoriasis	0.000173	0.00672	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TYK2—psoriasis	0.000168	0.00655	CbGpPWpGaD
Gliclazide—VEGFA—Bladder Cancer—TP53—psoriasis	0.000163	0.00633	CbGpPWpGaD
Gliclazide—ALB—Lipoprotein metabolism—APOE—psoriasis	0.000144	0.00562	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—IL6—psoriasis	0.000138	0.00538	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—CYP2S1—psoriasis	0.000137	0.00535	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—CYP2S1—psoriasis	0.000135	0.00528	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—IFNG—psoriasis	0.000135	0.00525	CbGpPWpGaD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—JUN—psoriasis	0.000135	0.00524	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—TNF—psoriasis	0.000134	0.00524	CbGpPWpGaD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—VDR—psoriasis	0.000134	0.0052	CbGpPWpGaD
Gliclazide—CYP2C19—Melatonin metabolism and effects—APOE—psoriasis	0.000133	0.00519	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL10—psoriasis	0.000133	0.00518	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—NFKB1—psoriasis	0.000131	0.00511	CbGpPWpGaD
Gliclazide—VEGFA—Betamethasone—Hydrocortisone—psoriasis	0.00013	0.0381	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Hydrocortisone—psoriasis	0.00013	0.0381	CbGdCrCtD
Gliclazide—VEGFA—Allograft Rejection—CXCL8—psoriasis	0.000125	0.00488	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—CYP2S1—psoriasis	0.000125	0.00488	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP2S1—psoriasis	0.000124	0.00481	CbGpPWpGaD
Gliclazide—VEGFA—Dexamethasone—Betamethasone—psoriasis	0.000121	0.0353	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Dexamethasone—psoriasis	0.000121	0.0353	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Triamcinolone—psoriasis	0.000118	0.0345	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Triamcinolone—psoriasis	0.000118	0.0345	CbGdCrCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—STAT3—psoriasis	0.000118	0.00459	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—SERPINB8—psoriasis	0.000118	0.00459	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—TYK2—psoriasis	0.000113	0.0044	CbGpPWpGaD
Gliclazide—ALB—Binding and Uptake of Ligands by Scavenger Receptors—APOE—psoriasis	0.000112	0.00438	CbGpPWpGaD
Gliclazide—VEGFA—Betamethasone—Prednisone—psoriasis	0.000112	0.0328	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Prednisone—psoriasis	0.000112	0.0328	CbGdCrCtD
Gliclazide—VEGFA—Dexamethasone—Prednisolone—psoriasis	0.00011	0.032	CbGdCrCtD
Gliclazide—VEGFA—Betamethasone—Prednisolone—psoriasis	0.00011	0.032	CbGdCrCtD
Gliclazide—VEGFA—Signaling by VEGF—TYK2—psoriasis	0.000107	0.00415	CbGpPWpGaD
Gliclazide—VEGFA—Differentiation Pathway—IL6—psoriasis	0.000105	0.00408	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PCNA—psoriasis	0.000103	0.00402	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—CAT—psoriasis	9.89e-05	0.00385	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—ITGAL—psoriasis	9.69e-05	0.00378	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—CRP—psoriasis	9.65e-05	0.00376	CbGpPWpGaD
Gliclazide—ALB—Lipid and lipoprotein metabolism—APOE—psoriasis	9.6e-05	0.00374	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NDUFA5—psoriasis	9.55e-05	0.00372	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—APOE—psoriasis	9.45e-05	0.00368	CbGpPWpGaD
Gliclazide—CYP2C9—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—psoriasis	9.31e-05	0.00363	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NDUFA5—psoriasis	9.26e-05	0.00361	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—CAT—psoriasis	9.24e-05	0.0036	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—CARM1—psoriasis	9.1e-05	0.00355	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL4—psoriasis	9.09e-05	0.00354	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IL6—psoriasis	9.01e-05	0.00351	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TP53—psoriasis	8.99e-05	0.0035	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—ICAM1—psoriasis	8.87e-05	0.00346	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—CP—psoriasis	8.87e-05	0.00346	CbGpPWpGaD
Gliclazide—VEGFA—Allograft Rejection—TNF—psoriasis	8.72e-05	0.0034	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—NFKBIA—psoriasis	8.67e-05	0.00338	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—CARM1—psoriasis	8.46e-05	0.0033	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP2S1—psoriasis	8.12e-05	0.00316	CbGpPWpGaD
Gliclazide—CYP2C19—Melatonin metabolism and effects—NFKB1—psoriasis	7.92e-05	0.00309	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP2S1—psoriasis	7.87e-05	0.00307	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—CAT—psoriasis	7.86e-05	0.00306	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—CRP—psoriasis	7.85e-05	0.00306	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—CXCL8—psoriasis	7.27e-05	0.00283	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—ICAM1—psoriasis	7.22e-05	0.00281	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—JUN—psoriasis	6.94e-05	0.0027	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HCAR2—psoriasis	6.86e-05	0.00267	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—JUN—psoriasis	6.76e-05	0.00263	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—IFNG—psoriasis	6.75e-05	0.00263	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—NFKB1—psoriasis	6.68e-05	0.0026	CbGpPWpGaD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—NFKB1—psoriasis	6.51e-05	0.00253	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—CRP—psoriasis	6.24e-05	0.00243	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TAGAP—psoriasis	5.94e-05	0.00232	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—JUN—psoriasis	5.77e-05	0.00225	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—JUN—psoriasis	5.75e-05	0.00224	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—ICAM1—psoriasis	5.73e-05	0.00223	CbGpPWpGaD
Gliclazide—ALB—SLC-mediated transmembrane transport—CP—psoriasis	5.63e-05	0.00219	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—NFKB1—psoriasis	5.62e-05	0.00219	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—NFKB1—psoriasis	5.53e-05	0.00216	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—IL6—psoriasis	5.52e-05	0.00215	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IFNG—psoriasis	5.49e-05	0.00214	CbGpPWpGaD
Gliclazide—Loss of consciousness—Dexamethasone—psoriasis	5.23e-05	0.000288	CcSEcCtD
Gliclazide—Loss of consciousness—Betamethasone—psoriasis	5.23e-05	0.000288	CcSEcCtD
Gliclazide—Dizziness—Mycophenolic acid—psoriasis	5.23e-05	0.000288	CcSEcCtD
Gliclazide—Epistaxis—Methotrexate—psoriasis	5.23e-05	0.000287	CcSEcCtD
Gliclazide—Paraesthesia—Prednisolone—psoriasis	5.23e-05	0.000287	CcSEcCtD
Gliclazide—Tachycardia—Triamcinolone—psoriasis	5.23e-05	0.000287	CcSEcCtD
Gliclazide—Mental disorder—Prednisone—psoriasis	5.22e-05	0.000287	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—IL6—psoriasis	5.21e-05	0.00203	CbGpPWpGaD
Gliclazide—Malnutrition—Prednisone—psoriasis	5.18e-05	0.000285	CcSEcCtD
Gliclazide—Erythema—Prednisone—psoriasis	5.18e-05	0.000285	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Hydrocortisone—psoriasis	5.18e-05	0.000285	CcSEcCtD
Gliclazide—Hyperhidrosis—Triamcinolone—psoriasis	5.18e-05	0.000285	CcSEcCtD
Gliclazide—Agranulocytosis—Methotrexate—psoriasis	5.17e-05	0.000284	CcSEcCtD
Gliclazide—Convulsion—Betamethasone—psoriasis	5.16e-05	0.000284	CcSEcCtD
Gliclazide—Convulsion—Dexamethasone—psoriasis	5.16e-05	0.000284	CcSEcCtD
Gliclazide—Feeling abnormal—Mycophenolate mofetil—psoriasis	5.14e-05	0.000283	CcSEcCtD
Gliclazide—Insomnia—Hydrocortisone—psoriasis	5.14e-05	0.000283	CcSEcCtD
Gliclazide—Hypertension—Betamethasone—psoriasis	5.14e-05	0.000283	CcSEcCtD
Gliclazide—Hypertension—Dexamethasone—psoriasis	5.14e-05	0.000283	CcSEcCtD
Gliclazide—Paraesthesia—Hydrocortisone—psoriasis	5.11e-05	0.000281	CcSEcCtD
Gliclazide—Gastrointestinal pain—Mycophenolate mofetil—psoriasis	5.1e-05	0.000281	CcSEcCtD
Gliclazide—Urticaria—Cyclosporine—psoriasis	5.08e-05	0.000279	CcSEcCtD
Gliclazide—Myalgia—Dexamethasone—psoriasis	5.07e-05	0.000279	CcSEcCtD
Gliclazide—Myalgia—Betamethasone—psoriasis	5.07e-05	0.000279	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—TNF—psoriasis	5.06e-05	0.00197	CbGpPWpGaD
Gliclazide—Body temperature increased—Cyclosporine—psoriasis	5.06e-05	0.000278	CcSEcCtD
Gliclazide—Abdominal pain—Cyclosporine—psoriasis	5.06e-05	0.000278	CcSEcCtD
Gliclazide—Anxiety—Betamethasone—psoriasis	5.05e-05	0.000278	CcSEcCtD
Gliclazide—Anxiety—Dexamethasone—psoriasis	5.05e-05	0.000278	CcSEcCtD
Gliclazide—Vomiting—Mycophenolic acid—psoriasis	5.03e-05	0.000276	CcSEcCtD
Gliclazide—Discomfort—Betamethasone—psoriasis	5.01e-05	0.000275	CcSEcCtD
Gliclazide—Discomfort—Dexamethasone—psoriasis	5.01e-05	0.000275	CcSEcCtD
Gliclazide—Dyspepsia—Hydrocortisone—psoriasis	5.01e-05	0.000275	CcSEcCtD
Gliclazide—Rash—Mycophenolic acid—psoriasis	4.99e-05	0.000274	CcSEcCtD
Gliclazide—Dermatitis—Mycophenolic acid—psoriasis	4.98e-05	0.000274	CcSEcCtD
Gliclazide—Pain—Prednisolone—psoriasis	4.98e-05	0.000274	CcSEcCtD
Gliclazide—Hepatitis—Methotrexate—psoriasis	4.98e-05	0.000274	CcSEcCtD
Gliclazide—Urticaria—Mycophenolate mofetil—psoriasis	4.96e-05	0.000273	CcSEcCtD
Gliclazide—Headache—Mycophenolic acid—psoriasis	4.96e-05	0.000272	CcSEcCtD
Gliclazide—Pharyngitis—Methotrexate—psoriasis	4.94e-05	0.000272	CcSEcCtD
Gliclazide—Abdominal pain—Mycophenolate mofetil—psoriasis	4.93e-05	0.000271	CcSEcCtD
Gliclazide—Body temperature increased—Mycophenolate mofetil—psoriasis	4.93e-05	0.000271	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Hydrocortisone—psoriasis	4.91e-05	0.00027	CcSEcCtD
Gliclazide—Fatigue—Hydrocortisone—psoriasis	4.9e-05	0.00027	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Triamcinolone—psoriasis	4.88e-05	0.000268	CcSEcCtD
Gliclazide—Pain—Hydrocortisone—psoriasis	4.86e-05	0.000267	CcSEcCtD
Gliclazide—Insomnia—Triamcinolone—psoriasis	4.84e-05	0.000266	CcSEcCtD
Gliclazide—Infection—Dexamethasone—psoriasis	4.83e-05	0.000265	CcSEcCtD
Gliclazide—Infection—Betamethasone—psoriasis	4.83e-05	0.000265	CcSEcCtD
Gliclazide—Ill-defined disorder—Prednisone—psoriasis	4.81e-05	0.000264	CcSEcCtD
Gliclazide—Paraesthesia—Triamcinolone—psoriasis	4.81e-05	0.000264	CcSEcCtD
Gliclazide—Feeling abnormal—Prednisolone—psoriasis	4.8e-05	0.000264	CcSEcCtD
Gliclazide—Visual impairment—Methotrexate—psoriasis	4.8e-05	0.000264	CcSEcCtD
Gliclazide—Anaemia—Prednisone—psoriasis	4.79e-05	0.000263	CcSEcCtD
Gliclazide—Dyspnoea—Triamcinolone—psoriasis	4.77e-05	0.000262	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—CXCL8—psoriasis	4.77e-05	0.00186	CbGpPWpGaD
Gliclazide—Nervous system disorder—Betamethasone—psoriasis	4.77e-05	0.000262	CcSEcCtD
Gliclazide—Nervous system disorder—Dexamethasone—psoriasis	4.77e-05	0.000262	CcSEcCtD
Gliclazide—Agitation—Prednisone—psoriasis	4.76e-05	0.000262	CcSEcCtD
Gliclazide—Thrombocytopenia—Betamethasone—psoriasis	4.76e-05	0.000262	CcSEcCtD
Gliclazide—Thrombocytopenia—Dexamethasone—psoriasis	4.76e-05	0.000262	CcSEcCtD
Gliclazide—Tachycardia—Betamethasone—psoriasis	4.74e-05	0.000261	CcSEcCtD
Gliclazide—Tachycardia—Dexamethasone—psoriasis	4.74e-05	0.000261	CcSEcCtD
Gliclazide—Angioedema—Prednisone—psoriasis	4.74e-05	0.00026	CcSEcCtD
Gliclazide—Hypersensitivity—Cyclosporine—psoriasis	4.71e-05	0.000259	CcSEcCtD
Gliclazide—Dyspepsia—Triamcinolone—psoriasis	4.71e-05	0.000259	CcSEcCtD
Gliclazide—Erythema multiforme—Methotrexate—psoriasis	4.71e-05	0.000259	CcSEcCtD
Gliclazide—Nausea—Mycophenolic acid—psoriasis	4.7e-05	0.000258	CcSEcCtD
Gliclazide—Hyperhidrosis—Dexamethasone—psoriasis	4.7e-05	0.000258	CcSEcCtD
Gliclazide—Hyperhidrosis—Betamethasone—psoriasis	4.7e-05	0.000258	CcSEcCtD
Gliclazide—Feeling abnormal—Hydrocortisone—psoriasis	4.69e-05	0.000258	CcSEcCtD
Gliclazide—Malaise—Prednisone—psoriasis	4.68e-05	0.000257	CcSEcCtD
Gliclazide—VEGFA—Axon guidance—TYK2—psoriasis	4.65e-05	0.00181	CbGpPWpGaD
Gliclazide—Eye disorder—Methotrexate—psoriasis	4.65e-05	0.000256	CcSEcCtD
Gliclazide—Gastrointestinal pain—Hydrocortisone—psoriasis	4.65e-05	0.000256	CcSEcCtD
Gliclazide—Tinnitus—Methotrexate—psoriasis	4.64e-05	0.000255	CcSEcCtD
Gliclazide—Urticaria—Prednisolone—psoriasis	4.63e-05	0.000254	CcSEcCtD
Gliclazide—Fatigue—Triamcinolone—psoriasis	4.62e-05	0.000254	CcSEcCtD
Gliclazide—Hypersensitivity—Mycophenolate mofetil—psoriasis	4.6e-05	0.000253	CcSEcCtD
Gliclazide—Asthenia—Cyclosporine—psoriasis	4.59e-05	0.000252	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—psoriasis	4.58e-05	0.00178	CbGpPWpGaD
Gliclazide—Pain—Triamcinolone—psoriasis	4.58e-05	0.000252	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—NFKB1—psoriasis	4.57e-05	0.00178	CbGpPWpGaD
Gliclazide—Loss of consciousness—Prednisone—psoriasis	4.56e-05	0.00025	CcSEcCtD
Gliclazide—Hypotension—Betamethasone—psoriasis	4.54e-05	0.00025	CcSEcCtD
Gliclazide—Hypotension—Dexamethasone—psoriasis	4.54e-05	0.00025	CcSEcCtD
Gliclazide—Pruritus—Cyclosporine—psoriasis	4.53e-05	0.000249	CcSEcCtD
Gliclazide—Urticaria—Hydrocortisone—psoriasis	4.52e-05	0.000248	CcSEcCtD
Gliclazide—Body temperature increased—Hydrocortisone—psoriasis	4.5e-05	0.000247	CcSEcCtD
Gliclazide—Abdominal pain—Hydrocortisone—psoriasis	4.5e-05	0.000247	CcSEcCtD
Gliclazide—Convulsion—Prednisone—psoriasis	4.49e-05	0.000247	CcSEcCtD
Gliclazide—Asthenia—Mycophenolate mofetil—psoriasis	4.48e-05	0.000246	CcSEcCtD
Gliclazide—Hypertension—Prednisone—psoriasis	4.48e-05	0.000246	CcSEcCtD
Gliclazide—Chills—Methotrexate—psoriasis	4.47e-05	0.000246	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—JUN—psoriasis	4.44e-05	0.00173	CbGpPWpGaD
Gliclazide—Musculoskeletal discomfort—Dexamethasone—psoriasis	4.43e-05	0.000243	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Betamethasone—psoriasis	4.43e-05	0.000243	CcSEcCtD
Gliclazide—Pruritus—Mycophenolate mofetil—psoriasis	4.42e-05	0.000243	CcSEcCtD
Gliclazide—Myalgia—Prednisone—psoriasis	4.41e-05	0.000243	CcSEcCtD
Gliclazide—Arthralgia—Prednisone—psoriasis	4.41e-05	0.000243	CcSEcCtD
Gliclazide—Feeling abnormal—Triamcinolone—psoriasis	4.41e-05	0.000243	CcSEcCtD
Gliclazide—Anxiety—Prednisone—psoriasis	4.4e-05	0.000242	CcSEcCtD
Gliclazide—Insomnia—Betamethasone—psoriasis	4.39e-05	0.000242	CcSEcCtD
Gliclazide—Insomnia—Dexamethasone—psoriasis	4.39e-05	0.000242	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Prednisone—psoriasis	4.38e-05	0.000241	CcSEcCtD
Gliclazide—Diarrhoea—Cyclosporine—psoriasis	4.38e-05	0.000241	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—TNF—psoriasis	4.37e-05	0.0017	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IFNG—psoriasis	4.36e-05	0.0017	CbGpPWpGaD
Gliclazide—Paraesthesia—Dexamethasone—psoriasis	4.36e-05	0.00024	CcSEcCtD
Gliclazide—Paraesthesia—Betamethasone—psoriasis	4.36e-05	0.00024	CcSEcCtD
Gliclazide—Discomfort—Prednisone—psoriasis	4.36e-05	0.00024	CcSEcCtD
Gliclazide—Mental disorder—Methotrexate—psoriasis	4.36e-05	0.00024	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—LEP—psoriasis	4.35e-05	0.00169	CbGpPWpGaD
Gliclazide—Erythema—Methotrexate—psoriasis	4.33e-05	0.000238	CcSEcCtD
Gliclazide—Malnutrition—Methotrexate—psoriasis	4.33e-05	0.000238	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TNF—psoriasis	4.3e-05	0.00168	CbGpPWpGaD
Gliclazide—Hypersensitivity—Prednisolone—psoriasis	4.29e-05	0.000236	CcSEcCtD
Gliclazide—Dyspepsia—Betamethasone—psoriasis	4.28e-05	0.000235	CcSEcCtD
Gliclazide—Dyspepsia—Dexamethasone—psoriasis	4.28e-05	0.000235	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—NFKB1—psoriasis	4.27e-05	0.00166	CbGpPWpGaD
Gliclazide—Diarrhoea—Mycophenolate mofetil—psoriasis	4.27e-05	0.000235	CcSEcCtD
Gliclazide—Urticaria—Triamcinolone—psoriasis	4.25e-05	0.000234	CcSEcCtD
Gliclazide—Body temperature increased—Triamcinolone—psoriasis	4.23e-05	0.000233	CcSEcCtD
Gliclazide—Dizziness—Cyclosporine—psoriasis	4.23e-05	0.000233	CcSEcCtD
Gliclazide—Infection—Prednisone—psoriasis	4.2e-05	0.000231	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Betamethasone—psoriasis	4.19e-05	0.000231	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Dexamethasone—psoriasis	4.19e-05	0.000231	CcSEcCtD
Gliclazide—Back pain—Methotrexate—psoriasis	4.19e-05	0.00023	CcSEcCtD
Gliclazide—Hypersensitivity—Hydrocortisone—psoriasis	4.19e-05	0.00023	CcSEcCtD
Gliclazide—Fatigue—Betamethasone—psoriasis	4.19e-05	0.00023	CcSEcCtD
Gliclazide—Fatigue—Dexamethasone—psoriasis	4.19e-05	0.00023	CcSEcCtD
Gliclazide—Pain—Dexamethasone—psoriasis	4.16e-05	0.000228	CcSEcCtD
Gliclazide—Pain—Betamethasone—psoriasis	4.16e-05	0.000228	CcSEcCtD
Gliclazide—Nervous system disorder—Prednisone—psoriasis	4.15e-05	0.000228	CcSEcCtD
Gliclazide—Tachycardia—Prednisone—psoriasis	4.13e-05	0.000227	CcSEcCtD
Gliclazide—Dizziness—Mycophenolate mofetil—psoriasis	4.13e-05	0.000227	CcSEcCtD
Gliclazide—Skin disorder—Prednisone—psoriasis	4.11e-05	0.000226	CcSEcCtD
Gliclazide—Hyperhidrosis—Prednisone—psoriasis	4.09e-05	0.000225	CcSEcCtD
Gliclazide—VEGFA—SIDS Susceptibility Pathways—IL6—psoriasis	4.08e-05	0.00159	CbGpPWpGaD
Gliclazide—Asthenia—Hydrocortisone—psoriasis	4.08e-05	0.000224	CcSEcCtD
Gliclazide—Vomiting—Cyclosporine—psoriasis	4.07e-05	0.000224	CcSEcCtD
Gliclazide—Rash—Cyclosporine—psoriasis	4.03e-05	0.000222	CcSEcCtD
Gliclazide—Dermatitis—Cyclosporine—psoriasis	4.03e-05	0.000222	CcSEcCtD
Gliclazide—Pruritus—Hydrocortisone—psoriasis	4.02e-05	0.000221	CcSEcCtD
Gliclazide—Ill-defined disorder—Methotrexate—psoriasis	4.02e-05	0.000221	CcSEcCtD
Gliclazide—Headache—Cyclosporine—psoriasis	4.01e-05	0.00022	CcSEcCtD
Gliclazide—Anaemia—Methotrexate—psoriasis	4e-05	0.00022	CcSEcCtD
Gliclazide—Feeling abnormal—Betamethasone—psoriasis	4e-05	0.00022	CcSEcCtD
Gliclazide—Feeling abnormal—Dexamethasone—psoriasis	4e-05	0.00022	CcSEcCtD
Gliclazide—VEGFA—Hemostasis—NOS2—psoriasis	3.98e-05	0.00155	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Betamethasone—psoriasis	3.97e-05	0.000218	CcSEcCtD
Gliclazide—Gastrointestinal pain—Dexamethasone—psoriasis	3.97e-05	0.000218	CcSEcCtD
Gliclazide—Vomiting—Mycophenolate mofetil—psoriasis	3.97e-05	0.000218	CcSEcCtD
Gliclazide—ABCC8—Metabolism—CARM1—psoriasis	3.96e-05	0.00154	CbGpPWpGaD
Gliclazide—Hypersensitivity—Triamcinolone—psoriasis	3.95e-05	0.000217	CcSEcCtD
Gliclazide—Rash—Mycophenolate mofetil—psoriasis	3.94e-05	0.000216	CcSEcCtD
Gliclazide—Dermatitis—Mycophenolate mofetil—psoriasis	3.93e-05	0.000216	CcSEcCtD
Gliclazide—Headache—Mycophenolate mofetil—psoriasis	3.91e-05	0.000215	CcSEcCtD
Gliclazide—Malaise—Methotrexate—psoriasis	3.91e-05	0.000215	CcSEcCtD
Gliclazide—Diarrhoea—Hydrocortisone—psoriasis	3.89e-05	0.000214	CcSEcCtD
Gliclazide—Leukopenia—Methotrexate—psoriasis	3.88e-05	0.000213	CcSEcCtD
Gliclazide—Urticaria—Betamethasone—psoriasis	3.86e-05	0.000212	CcSEcCtD
Gliclazide—Urticaria—Dexamethasone—psoriasis	3.86e-05	0.000212	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Prednisone—psoriasis	3.86e-05	0.000212	CcSEcCtD
Gliclazide—Dizziness—Prednisolone—psoriasis	3.85e-05	0.000212	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—CARM1—psoriasis	3.84e-05	0.0015	CbGpPWpGaD
Gliclazide—Asthenia—Triamcinolone—psoriasis	3.84e-05	0.000211	CcSEcCtD
Gliclazide—Body temperature increased—Betamethasone—psoriasis	3.84e-05	0.000211	CcSEcCtD
Gliclazide—Abdominal pain—Betamethasone—psoriasis	3.84e-05	0.000211	CcSEcCtD
Gliclazide—Abdominal pain—Dexamethasone—psoriasis	3.84e-05	0.000211	CcSEcCtD
Gliclazide—Body temperature increased—Dexamethasone—psoriasis	3.84e-05	0.000211	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—STAT3—psoriasis	3.84e-05	0.0015	CbGpPWpGaD
Gliclazide—Insomnia—Prednisone—psoriasis	3.83e-05	0.00021	CcSEcCtD
Gliclazide—Nausea—Cyclosporine—psoriasis	3.8e-05	0.000209	CcSEcCtD
Gliclazide—Paraesthesia—Prednisone—psoriasis	3.8e-05	0.000209	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—psoriasis	3.8e-05	0.00148	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—PPARG—psoriasis	3.79e-05	0.00148	CbGpPWpGaD
Gliclazide—Pruritus—Triamcinolone—psoriasis	3.79e-05	0.000208	CcSEcCtD
Gliclazide—Cough—Methotrexate—psoriasis	3.78e-05	0.000208	CcSEcCtD
Gliclazide—Dizziness—Hydrocortisone—psoriasis	3.76e-05	0.000207	CcSEcCtD
Gliclazide—Convulsion—Methotrexate—psoriasis	3.75e-05	0.000206	CcSEcCtD
Gliclazide—Dyspepsia—Prednisone—psoriasis	3.72e-05	0.000205	CcSEcCtD
Gliclazide—Nausea—Mycophenolate mofetil—psoriasis	3.71e-05	0.000204	CcSEcCtD
Gliclazide—Chest pain—Methotrexate—psoriasis	3.69e-05	0.000203	CcSEcCtD
Gliclazide—Arthralgia—Methotrexate—psoriasis	3.69e-05	0.000203	CcSEcCtD
Gliclazide—Myalgia—Methotrexate—psoriasis	3.69e-05	0.000203	CcSEcCtD
Gliclazide—Rash—Prednisolone—psoriasis	3.67e-05	0.000202	CcSEcCtD
Gliclazide—Dermatitis—Prednisolone—psoriasis	3.67e-05	0.000202	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—psoriasis	3.66e-05	0.000201	CcSEcCtD
Gliclazide—Fatigue—Prednisone—psoriasis	3.65e-05	0.000201	CcSEcCtD
Gliclazide—Headache—Prednisolone—psoriasis	3.65e-05	0.000201	CcSEcCtD
Gliclazide—Discomfort—Methotrexate—psoriasis	3.64e-05	0.0002	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—NFKB1—psoriasis	3.63e-05	0.00141	CbGpPWpGaD
Gliclazide—Constipation—Prednisone—psoriasis	3.62e-05	0.000199	CcSEcCtD
Gliclazide—Vomiting—Hydrocortisone—psoriasis	3.62e-05	0.000199	CcSEcCtD
Gliclazide—Rash—Hydrocortisone—psoriasis	3.59e-05	0.000197	CcSEcCtD
Gliclazide—Dermatitis—Hydrocortisone—psoriasis	3.58e-05	0.000197	CcSEcCtD
Gliclazide—Confusional state—Methotrexate—psoriasis	3.57e-05	0.000196	CcSEcCtD
Gliclazide—Headache—Hydrocortisone—psoriasis	3.56e-05	0.000196	CcSEcCtD
Gliclazide—VEGFA—Signaling Pathways—CCL20—psoriasis	3.56e-05	0.00139	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—VEGFA—psoriasis	3.56e-05	0.00139	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TNF—psoriasis	3.55e-05	0.00138	CbGpPWpGaD
Gliclazide—Dizziness—Triamcinolone—psoriasis	3.54e-05	0.000195	CcSEcCtD
Gliclazide—ALB—Vitamin B12 Metabolism—IL6—psoriasis	3.53e-05	0.00137	CbGpPWpGaD
Gliclazide—Infection—Methotrexate—psoriasis	3.51e-05	0.000193	CcSEcCtD
Gliclazide—Feeling abnormal—Prednisone—psoriasis	3.49e-05	0.000192	CcSEcCtD
Gliclazide—Asthenia—Dexamethasone—psoriasis	3.49e-05	0.000192	CcSEcCtD
Gliclazide—Asthenia—Betamethasone—psoriasis	3.49e-05	0.000192	CcSEcCtD
Gliclazide—Nervous system disorder—Methotrexate—psoriasis	3.47e-05	0.000191	CcSEcCtD
Gliclazide—Thrombocytopenia—Methotrexate—psoriasis	3.46e-05	0.00019	CcSEcCtD
Gliclazide—Gastrointestinal pain—Prednisone—psoriasis	3.46e-05	0.00019	CcSEcCtD
Gliclazide—Nausea—Prednisolone—psoriasis	3.46e-05	0.00019	CcSEcCtD
Gliclazide—Pruritus—Dexamethasone—psoriasis	3.44e-05	0.000189	CcSEcCtD
Gliclazide—Pruritus—Betamethasone—psoriasis	3.44e-05	0.000189	CcSEcCtD
Gliclazide—Skin disorder—Methotrexate—psoriasis	3.43e-05	0.000189	CcSEcCtD
Gliclazide—ALB—Hemostasis—ITGAL—psoriasis	3.42e-05	0.00133	CbGpPWpGaD
Gliclazide—Hyperhidrosis—Methotrexate—psoriasis	3.42e-05	0.000188	CcSEcCtD
Gliclazide—Vomiting—Triamcinolone—psoriasis	3.4e-05	0.000187	CcSEcCtD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—psoriasis	3.39e-05	0.00132	CbGpPWpGaD
Gliclazide—Nausea—Hydrocortisone—psoriasis	3.38e-05	0.000186	CcSEcCtD
Gliclazide—Rash—Triamcinolone—psoriasis	3.38e-05	0.000186	CcSEcCtD
Gliclazide—Dermatitis—Triamcinolone—psoriasis	3.37e-05	0.000185	CcSEcCtD
Gliclazide—Urticaria—Prednisone—psoriasis	3.36e-05	0.000185	CcSEcCtD
Gliclazide—Headache—Triamcinolone—psoriasis	3.35e-05	0.000184	CcSEcCtD
Gliclazide—Body temperature increased—Prednisone—psoriasis	3.35e-05	0.000184	CcSEcCtD
Gliclazide—Abdominal pain—Prednisone—psoriasis	3.35e-05	0.000184	CcSEcCtD
Gliclazide—Diarrhoea—Dexamethasone—psoriasis	3.32e-05	0.000183	CcSEcCtD
Gliclazide—Diarrhoea—Betamethasone—psoriasis	3.32e-05	0.000183	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—TYK2—psoriasis	3.32e-05	0.00129	CbGpPWpGaD
Gliclazide—Hypotension—Methotrexate—psoriasis	3.3e-05	0.000182	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Methotrexate—psoriasis	3.22e-05	0.000177	CcSEcCtD
Gliclazide—Dizziness—Dexamethasone—psoriasis	3.21e-05	0.000177	CcSEcCtD
Gliclazide—Dizziness—Betamethasone—psoriasis	3.21e-05	0.000177	CcSEcCtD
Gliclazide—Insomnia—Methotrexate—psoriasis	3.2e-05	0.000176	CcSEcCtD
Gliclazide—Nausea—Triamcinolone—psoriasis	3.18e-05	0.000175	CcSEcCtD
Gliclazide—Paraesthesia—Methotrexate—psoriasis	3.18e-05	0.000175	CcSEcCtD
Gliclazide—Dyspnoea—Methotrexate—psoriasis	3.15e-05	0.000173	CcSEcCtD
Gliclazide—Somnolence—Methotrexate—psoriasis	3.14e-05	0.000173	CcSEcCtD
Gliclazide—ALB—Folate Metabolism—TP53—psoriasis	3.13e-05	0.00122	CbGpPWpGaD
Gliclazide—Hypersensitivity—Prednisone—psoriasis	3.12e-05	0.000171	CcSEcCtD
Gliclazide—Dyspepsia—Methotrexate—psoriasis	3.11e-05	0.000171	CcSEcCtD
Gliclazide—Vomiting—Betamethasone—psoriasis	3.09e-05	0.00017	CcSEcCtD
Gliclazide—Vomiting—Dexamethasone—psoriasis	3.09e-05	0.00017	CcSEcCtD
Gliclazide—ALB—Metabolism—NDUFA5—psoriasis	3.08e-05	0.0012	CbGpPWpGaD
Gliclazide—Rash—Dexamethasone—psoriasis	3.06e-05	0.000168	CcSEcCtD
Gliclazide—Rash—Betamethasone—psoriasis	3.06e-05	0.000168	CcSEcCtD
Gliclazide—Dermatitis—Betamethasone—psoriasis	3.06e-05	0.000168	CcSEcCtD
Gliclazide—Dermatitis—Dexamethasone—psoriasis	3.06e-05	0.000168	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Methotrexate—psoriasis	3.05e-05	0.000168	CcSEcCtD
Gliclazide—Fatigue—Methotrexate—psoriasis	3.05e-05	0.000168	CcSEcCtD
Gliclazide—Headache—Betamethasone—psoriasis	3.04e-05	0.000167	CcSEcCtD
Gliclazide—Headache—Dexamethasone—psoriasis	3.04e-05	0.000167	CcSEcCtD
Gliclazide—Asthenia—Prednisone—psoriasis	3.04e-05	0.000167	CcSEcCtD
Gliclazide—Pain—Methotrexate—psoriasis	3.02e-05	0.000166	CcSEcCtD
Gliclazide—Pruritus—Prednisone—psoriasis	2.99e-05	0.000165	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—TP53—psoriasis	2.93e-05	0.00114	CbGpPWpGaD
Gliclazide—Feeling abnormal—Methotrexate—psoriasis	2.91e-05	0.00016	CcSEcCtD
Gliclazide—Diarrhoea—Prednisone—psoriasis	2.9e-05	0.000159	CcSEcCtD
Gliclazide—Gastrointestinal pain—Methotrexate—psoriasis	2.89e-05	0.000159	CcSEcCtD
Gliclazide—Nausea—Dexamethasone—psoriasis	2.89e-05	0.000159	CcSEcCtD
Gliclazide—Nausea—Betamethasone—psoriasis	2.89e-05	0.000159	CcSEcCtD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.87e-05	0.00112	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL6—psoriasis	2.87e-05	0.00112	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—CP—psoriasis	2.86e-05	0.00111	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—TNF—psoriasis	2.82e-05	0.0011	CbGpPWpGaD
Gliclazide—Urticaria—Methotrexate—psoriasis	2.81e-05	0.000154	CcSEcCtD
Gliclazide—Dizziness—Prednisone—psoriasis	2.8e-05	0.000154	CcSEcCtD
Gliclazide—Abdominal pain—Methotrexate—psoriasis	2.8e-05	0.000154	CcSEcCtD
Gliclazide—Body temperature increased—Methotrexate—psoriasis	2.8e-05	0.000154	CcSEcCtD
Gliclazide—CYP2C19—Metabolism—NDUFA5—psoriasis	2.76e-05	0.00108	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—CARM1—psoriasis	2.73e-05	0.00106	CbGpPWpGaD
Gliclazide—Vomiting—Prednisone—psoriasis	2.69e-05	0.000148	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—IL6—psoriasis	2.68e-05	0.00104	CbGpPWpGaD
Gliclazide—Rash—Prednisone—psoriasis	2.67e-05	0.000147	CcSEcCtD
Gliclazide—Dermatitis—Prednisone—psoriasis	2.67e-05	0.000147	CcSEcCtD
Gliclazide—Headache—Prednisone—psoriasis	2.65e-05	0.000146	CcSEcCtD
Gliclazide—ALB—Metabolism—CYP2S1—psoriasis	2.62e-05	0.00102	CbGpPWpGaD
Gliclazide—Hypersensitivity—Methotrexate—psoriasis	2.61e-05	0.000143	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—NFKB1—psoriasis	2.59e-05	0.00101	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.58e-05	0.001	CbGpPWpGaD
Gliclazide—Asthenia—Methotrexate—psoriasis	2.54e-05	0.000139	CcSEcCtD
Gliclazide—CYP2C9—Metabolism—NDUFA5—psoriasis	2.52e-05	0.000981	CbGpPWpGaD
Gliclazide—Nausea—Prednisone—psoriasis	2.51e-05	0.000138	CcSEcCtD
Gliclazide—Pruritus—Methotrexate—psoriasis	2.5e-05	0.000138	CcSEcCtD
Gliclazide—ABCC8—Metabolism—CAT—psoriasis	2.44e-05	0.00095	CbGpPWpGaD
Gliclazide—Diarrhoea—Methotrexate—psoriasis	2.42e-05	0.000133	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—CAT—psoriasis	2.36e-05	0.000921	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP2S1—psoriasis	2.35e-05	0.000915	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CARM1—psoriasis	2.35e-05	0.000915	CbGpPWpGaD
Gliclazide—Dizziness—Methotrexate—psoriasis	2.34e-05	0.000129	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—STAT3—psoriasis	2.33e-05	0.000906	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—IL6—psoriasis	2.28e-05	0.000888	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—IL6—psoriasis	2.28e-05	0.000887	CbGpPWpGaD
Gliclazide—Vomiting—Methotrexate—psoriasis	2.25e-05	0.000124	CcSEcCtD
Gliclazide—Rash—Methotrexate—psoriasis	2.23e-05	0.000123	CcSEcCtD
Gliclazide—Dermatitis—Methotrexate—psoriasis	2.23e-05	0.000122	CcSEcCtD
Gliclazide—Headache—Methotrexate—psoriasis	2.22e-05	0.000122	CcSEcCtD
Gliclazide—CYP2C9—Metabolism—CYP2S1—psoriasis	2.14e-05	0.000834	CbGpPWpGaD
Gliclazide—Nausea—Methotrexate—psoriasis	2.1e-05	0.000115	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—TNF—psoriasis	2.01e-05	0.000784	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—SOCS1—psoriasis	1.96e-05	0.000764	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—APOE—psoriasis	1.89e-05	0.000738	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—APOE—psoriasis	1.84e-05	0.000715	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—psoriasis	1.74e-05	0.000678	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PPARG—psoriasis	1.65e-05	0.000643	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—IL6—psoriasis	1.62e-05	0.000633	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PPARG—psoriasis	1.6e-05	0.000623	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—psoriasis	1.58e-05	0.000614	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—LEP—psoriasis	1.45e-05	0.000564	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—APOE—psoriasis	1.45e-05	0.000564	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—NOS2—psoriasis	1.4e-05	0.000547	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.37e-05	0.000534	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NFKBIA—psoriasis	1.35e-05	0.000525	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CARM1—psoriasis	1.28e-05	0.000498	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.23e-05	0.00048	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.19e-05	0.000465	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CARM1—psoriasis	1.15e-05	0.000447	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—APOE—psoriasis	1.12e-05	0.000437	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TYK2—psoriasis	1.1e-05	0.00043	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PPARG—psoriasis	1.07e-05	0.000418	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CARM1—psoriasis	1.05e-05	0.000407	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PPARG—psoriasis	9.78e-06	0.000381	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CXCL8—psoriasis	9.62e-06	0.000375	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—JUN—psoriasis	8.94e-06	0.000348	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NFKB1—psoriasis	8.61e-06	0.000335	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—psoriasis	8.13e-06	0.000317	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CAT—psoriasis	7.86e-06	0.000306	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—psoriasis	7.73e-06	0.000301	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CAT—psoriasis	7.06e-06	0.000275	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CAT—psoriasis	6.43e-06	0.000251	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—psoriasis	6.14e-06	0.000239	CbGpPWpGaD
Gliclazide—ALB—Metabolism—APOE—psoriasis	6.11e-06	0.000238	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—psoriasis	5.9e-06	0.00023	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—APOE—psoriasis	5.48e-06	0.000214	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL6—psoriasis	5.4e-06	0.00021	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PPARG—psoriasis	5.32e-06	0.000207	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—APOE—psoriasis	5e-06	0.000195	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PPARG—psoriasis	4.78e-06	0.000186	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PPARG—psoriasis	4.35e-06	0.00017	CbGpPWpGaD
